A biallelic pathogenic variant in the OGDH gene results in a neurological disorder with features of a mitochondrial disease

2‐Oxoglutarate dehydrogenase (OGDH) is a rate‐limiting enzyme in the mitochondrial TCA cycle, encoded by the OGDH gene. α‐Ketoglutarate dehydrogenase (OGDH) deficiency was previously reported in association with developmental delay, hypotonia, and movement disorders and metabolic decompensation, wit...

Full description

Saved in:
Bibliographic Details
Published inJournal of inherited metabolic disease Vol. 44; no. 2; pp. 388 - 400
Main Authors Yap, Zheng Yie, Strucinska, Klaudia, Matsuzaki, Satoshi, Lee, Sukyeong, Si, Yue, Humphries, Kenneth, Tarnopolsky, Mark A., Yoon, Wan Hee
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.03.2021
Blackwell Publishing Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:2‐Oxoglutarate dehydrogenase (OGDH) is a rate‐limiting enzyme in the mitochondrial TCA cycle, encoded by the OGDH gene. α‐Ketoglutarate dehydrogenase (OGDH) deficiency was previously reported in association with developmental delay, hypotonia, and movement disorders and metabolic decompensation, with no genetic data provided. Using whole exome sequencing, we identified two individuals carrying a homozygous missense variant c.959A>G (p.N320S) in the OGDH gene. These individuals presented with global developmental delay, elevated lactate, ataxia and seizure. Fibroblast analysis and modeling of the mutation in Drosophila were used to evaluate pathogenicity of the variant. Skin fibroblasts from subject # 2 showed a decrease in both OGDH protein and enzyme activity. Transfection of human OGDH cDNA in HEK293 cells carrying p.N320S also produced significantly lower protein levels compared to those with wild‐type cDNA. Loss of Drosophila Ogdh (dOgdh) caused early developmental lethality, rescued by expressing wild‐type dOgdh (dOgdhWT) or human OGDH (OGDHWT) cDNA. In contrast, expression to the mutant OGDH (OGDHN320S) or dOgdh carrying homologous mutations to human OGDH p.N320S variant (dOgdhN324S) failed to rescue lethality of dOgdh null mutants. Knockdown of dOgdh in the nervous system resulted in locomotion defects which were rescued by dOgdhWT expression but not by dOgdhN324S expression. Collectively, the results indicate that c.959A>G variant in OGDH leads to an amino acid change (p.N320S) causing a severe loss of OGDH protein function. Our study establishes in the first time a genetic link between an OGDH gene mutation and OGDH deficiency.
Bibliography:Funding information
Mark A. Tarnopolsky and Wan Hee Yoon contributed equally to this study.
Areeg El‐Gharbawy
Canadian Institute of Health Science, Grant/Award Number: 143325; National Institutes of Health, Grant/Award Numbers: 5 P20 GM103636‐07, R01HL125625, R01‐GM111084, P01‐HD087157; Dan Wright and family; Warren Lammert and Family; Presbyterian Health Foundation, Grant/Award Number: 4411‐05‐07‐0
Communicating Editor
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
AUTHOR CONTRIBUTIONS
Zheng Yie Yap, Klaudia Strucinska, Satoshi Matsuzaki, Sukyeong Lee, Kenneth Humphries performed the in vitro work and fly experiments and provided figures and read and approved the manuscript. Yue Si performed the NGS and the Sanger testing of the patients and siblings and provided genetic testing data for the study and read and approved the manuscript. Mark A. Tarnopolsky examined all the patients and provided all clinical data, wrote the first draft of the manuscript and revised the manuscript and provided final approval for the submission. Wan Hee Yoon designed and supervised the in vitro work and fly experiments and added this to the manuscript and the revision and provided final approval for the submission.
ISSN:0141-8955
1573-2665
1573-2665
DOI:10.1002/jimd.12248